HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful use of infliximab therapy in sight-threatening corticosteroid-resistant Vogt-Koyanagi-Harada disease.

AbstractPURPOSE:
To report an experience with infliximab in severe corticosteroid-resistant Vogt-Koyanagi-Harada (VKH) disease.
DESIGN:
Interventional case series.
METHODS:
The medical records of 2 adult patients were reviewed.
RESULTS:
Both patients had a visual acuity reduced to hand motion perception bilaterally after 1 month of high-dose corticosteroid therapy, due to multiple exudative retinal detachment involving the fovea. Visual acuity and OCT findings improved immediately after the first infliximab infusion, retinal detachments fully resolved after 1 month and visual acuity returned to normal within 6 months. Despite a negative pretreatment screening, one patient developed multivisceral tuberculosis, which led to infliximab discontinuation after the 7th infusion and was cured by a 9-month ambulatory antibiotic regimen. The other patient received 11 well-tolerated infliximab infusions. Respectively, 9 and 4 months after infliximab discontinuation both patients had normal vision and OCT findings.
CONCLUSION:
Infliximab showed tremendous therapeutic efficacy in sight-threatening corticosteroid-resistant VKH disease.
AuthorsMathieu Zmuda, Kiet Phong Tiev, Juliette Knoeri, Emmanuel Héron
JournalOcular immunology and inflammation (Ocul Immunol Inflamm) Vol. 21 Issue 4 Pg. 310-6 (Aug 2013) ISSN: 1744-5078 [Electronic] England
PMID23617262 (Publication Type: Case Reports, Letter)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Diagnosis, Differential
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Infliximab
  • Middle Aged
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Uveomeningoencephalitic Syndrome (diagnosis, drug therapy, physiopathology)
  • Visual Acuity
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: